Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 May 18;23(1):189.
doi: 10.1186/s12882-022-02751-5.

Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France

Jean-François Verdier  1 , Sonia Boyer  2 , Florence Chalmin  2 , Ahmed Jeribi  2 , Caroline Egasse  2 , Marie France Maggi  3 , Philippe Auvray  2 , Tarik Yalaoui  4
Affiliations
Observational Study

Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France

Jean-François Verdier et al. BMC Nephrol. .

Abstract

Background: The mortality rate associated with coronavirus disease 2019 (COVID-19) is high among haemodialyzed patients. We sought to describe the serological status of haemodialysis patients having received up to three doses of BNT162b2 mRNA vaccine, and to identify factors associated with a poor humoral response.

Methods: We performed a retrospective, observational study of patients attending a dialysis centre in Antibes, France. One or two of each patient's monthly venous blood samples were assayed for anti-spike (S1) immunoglobulin G (IgG).

Results: We included 142 patients, of whom 124 remained COVID-19-negative throughout the study. Among these COVID-19-negative patients, the humoral immune response rate (defined as an anti-S1 IgG titre ≥1.2 U/ml) was 82.9% after two injections and 95.8% after three injections, and the median [interquartile range] titre increased significantly from 7.09 [2.21; 19.94] U/ml with two injections to 93.26 [34.25; 176.06] U/ml with three. Among patients with two injections, the mean body mass index and serum albumin levels were significantly higher in responders than in non-responders (26.5 kg/m2 vs. 23.2 kg/m2, p = 0.0392; and 41.9 g/l vs. 39.0 g/l, p = 0.0042, respectively). For the study population as a whole at the end of the study, a history of COVID-19, at least two vaccine doses, and being on the French national waiting list for kidney transplantation were the only factors independently associated with the anti-S1 IgG titre.

Conclusions: Dialysis patients vaccinated with two doses of BNT162b2 might not be sufficiently protected against SARS-CoV-2 and so should receive a third (booster) dose.

Trial registration: The present retrospective study of clinical practice was not interventional and so was not registered.

Keywords: COVID-19; Comirnaty; Haemodialysis; SARS-CoV-2; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Jean-François Verdier, Sonia Boyer, Florence Chalmin, Ahmed Jeribi, Caroline Egasse and Philippe Auvray are employed by or under contract with the Centre de Néphrologie d’Antibes/Centre d’Hémodialyse de la Riviera. Marie France Maggi is employed by Laboratoire Bioesterel. Tarik Yalaoui is employed by B. Braun Medical SAS, Saint-Cloud, France. None of the authors have other conflicts of interest to report.

Figures

Fig. 1
Fig. 1
Study timeline. It should be noted that not all participants received three doses of vaccine, and that the vaccination dates varied from one participant to another. Hence, the figure shows the sequence of events for a typical participant with three doses and two serology assays
Fig. 2
Fig. 2
Study flow chart
Fig. 3
Fig. 3
Individual anti-S1 Ig titres for COVID-19-negative patients. Data are shown as a function of the number of doses of vaccine received. Each grey line represents the change in an individual patient’s titre between the first and second serology assays (Ser1 and Ser2). The thick, black line was derived by non-parametric, locally estimated smoothing; it illustrates the trend for the group
Fig. 4
Fig. 4
Correlation between the anti-S1 Ig titre and age. Data are shown for patients with two or three doses of vaccine (n = 111) for the first (a) and second (b) serology assays
Fig. 5
Fig. 5
Correlation between the anti-S1 Ig titre and the anti-HBV titre. Data are shown for the first (a) and second (b) serology assays
See this image and copyright information in PMC

References

    1. Garcia-Montero C, Fraile-Martinez O, Bravo C, Torres-Carranza D, Sanchez-Trujillo L, Gomez-Lahoz AM, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines (Basel). 2021;9(5):433. - PMC - PubMed
    1. Hasan T, Beardsley J, Marais BJ, Nguyen TA, Fox GJ. The implementation of mass-vaccination against SARS-CoV-2: a systematic review of existing strategies and guidelines. Vaccines (Basel). 2021;9(4):326. - PMC - PubMed
    1. Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sanchez-Alvarez JE, Garneata L, Collart F, Hemmelder MH, Ambuhl P, Kerschbaum J, et al. Results from the ERA-EDTA registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540–1548. doi: 10.1016/j.kint.2020.09.006. - DOI - PMC - PubMed
    1. Ng JH, Hirsch JS, Wanchoo R, Sachdeva M, Sakhiya V, Hong S, Jhaveri KD, Fishbane S. Northwell C-RC, the Northwell nephrology C-RC: outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98(6):1530–1539. doi: 10.1016/j.kint.2020.07.030. - DOI - PMC - PubMed
    1. Francis A, Baigent C, Ikizler TA, Cockwell P, Jha V. The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. Kidney Int. 2021;99(4):791–793. doi: 10.1016/j.kint.2021.02.003. - DOI - PMC - PubMed

Publication types